



Meda's rights issue oversubscribed

- 11,592,196 shares, corresponding to 99.84 per cent of the offered shares, have been subscribed through exercise of subscription rights
- Including the shares that have been subscribed for without preferential rights, the rights issue has been oversubscribed by approximately 56 per cent
- The issue generated SEK 1,858 million before issue costs

11,592,196 shares, corresponding to 99.84 per cent of the offered shares, have been subscribed through exercise of subscription rights in Meda's rights issue. Including the shares that have been subscribed for without preferential rights, the rights issue has been oversubscribed by approximately 56 per cent. The issue generated SEK 1,858 million, before issue costs.

The 18,288 shares that have not been subscribed for through exercise of subscription rights, corresponding to 0.16 per cent of the total number of offered shares, will be allotted to those shareholders who subscribed for shares without preferential rights in accordance with principles set forth in the prospectus.

Through the rights issue the number of shares in Meda increases by 11,610,484 shares and the share capital increases by SEK 23,220,968. After the rights issue the total number of shares in Meda amounts to 116,104,842 shares and the share capital to SEK 232,209,684. The last trading day with the paid-up subscribed shares (BTA) is expected to be 20 February 2007. The newly issued shares are expected to be traded on the Stockholm Stock Exchange (Stockholmsbörsen) starting Thursday, 1 March 2007.

"The acquisition of 3M's European pharmaceutical division positions Meda as a leading European specialty pharma company. It is very gratifying that the company's shareholders have confidence in our further build-up" says Anders Lönner, CEO of Meda.

SEB Enskilda is acting as financial advisor to Meda AB for the rights issue.

Solna, Sweden, 13 February 2007

Meda AB (publ)

For more information, please contact:

Anders Lönner, CEO, +46 (0)8 630 19 00

Anders Larnholt, Investor Relations, +46 (0)8 630 19 62 or +46 (0)709 458 878

MEDA AB (publ) is a leading European specialty pharma company that concentrates on marketing and market-adapted product development. Acquisitions and long-term partnerships are fundamental factors that drive the company's strategy. Meda has own affiliates in 24 countries and more than 1,000 employees within marketing and sales. The Meda share is listed under Large Cap on the OMX Nordic Stock Exchange. Find out more, visit www.meda.se.